A Study of SR58611A in the Prevention of Depression Relapse in Patients With Major Depressive Disorder

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

704 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-05-31

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to assess whether treatment with SR58611A can prevent relapse of depressive symptoms in patients with major depressive disorder. Relapse will be assessed using the MADRS scale.Patients who demonstrate improvement in depressive symptoms at the end of the initial 12-week open-label treatment period with SR58611A are randomized to continue SR58611A or switch to placebo under double blind conditions for up to 52 weeks of additional treatment. The secondary objective is to evaluate the safety of SR58611A in patients with MDD.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00256113

Depressive Disorder

COMPLETED PHASE3

An Eight-Week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00250627

Depressive Disorder

COMPLETED PHASE3

A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)

NCT00336713

Depressive Disorder

COMPLETED PHASE3

An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Depression

NCT00250614

Depressive Disorder

COMPLETED PHASE3

Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovered From Depressive Symptoms With a Current Antidepressant Treatment

NCT02805439

Major Depressive Disorder

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Depressive Disorder Major Depression

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Investigators

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SR58611A

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients diagnosed with Major Depressive Disorder, Recurrent according to DSM-IV-TR criteria Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) and assessed with the Mini International Neuropsychiatric Interview (MINI)
* Total score on the Montgomery and Asberg Depression Rating Scale (MADRS) \> 28
* At W12 (V7), patients will be randomized into the double-blind treatment phase if they have MADRS total score \< 12

Exclusion Criteria

* Patients with a significant risk of suicide.
* Patients whose current depressive episode is diagnosed with psychotic features, catatonic features, seasonal pattern or post-partum onset.
* Patients with a current depressive episode secondary to a general medical disorder.
* Patients with a lifetime history or presence of bipolar disorder, psychotic disorder, panic disorder and antisocial personality disorder.
* Patients with severe or unstable concomitant medical conditions
* Patients with clinically significant abnormal laboratory value at screening
* The investigator will evaluate whether there are other reasons why a patient may not participate

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No